Deutsche Bank raised the firm’s price target on Spyre Therapeutics (SYRE) to $88 from $55 and keeps a Buy rating on the shares. The firm cites the company’s positive topline results for SPY001 in ulcerative colitis for the target bump. The SPY001 data were “impressive and came in above expectations,” particularly clinical remission of 40% at week 12, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Closing Bell Movers: Bloom Energy spikes on expanded Oracle deal
- Spyre Therapeutics announces $300M offering of common stock
- Spyre Therapeutics Pauses At-The-Market Equity Offering Program
- Spyre Therapeutics initiated with a Strong Buy at Raymond James
- Buy Rating on SYRE: Early SPY001 Outperformance, Broad IBD Opportunity, and Catalyst‑Rich Path Support Higher $80 Target